1. Home
  2. BQ vs ACXP Comparison

BQ vs ACXP Comparison

Compare BQ & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.80

Market Cap

5.9M

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.44

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
ACXP
Founded
2008
2017
Country
China
United States
Employees
N/A
4
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BQ
ACXP
Price
$0.80
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
120.5K
88.0K
Earning Date
01-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$1.33
52 Week High
$72.74
$8.34

Technical Indicators

Market Signals
Indicator
BQ
ACXP
Relative Strength Index (RSI) 43.52 40.02
Support Level $0.69 $1.36
Resistance Level $0.89 $1.75
Average True Range (ATR) 0.06 0.10
MACD -0.01 -0.00
Stochastic Oscillator 26.17 9.35

Price Performance

Historical Comparison
BQ
ACXP

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: